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Abstract 
The American Heart Association recently published an updated scientific statement on the 
management of infective endocarditis in childhood. The recommendations included for 
vancomycin, aminoglycoside, and β-lactam dosing and monitoring are based primarily on expert 
opinion and do not consider available evidence for dose optimization based on pharmacokinetic 
and pharmacodynamic principles in pediatric patients. This is concerning because even when 
clinically necessary, some practitioners may be hesitant to deviate from guideline-recommended 
doses. In this perspective, we highlight potential areas for improvement in the statement-
recommended doses and summarize evidence supporting antibiotic dosing optimization. The 
addition of a pediatric clinical pharmacist with expertise in antibiotic dosing to the panel would 
be beneficial for future updates. 
 
With the ever-expanding medical literature, well-formulated evidence-based guidelines, 
scientific statements, and recommendations are highly useful tools for clinicians. We were, 
therefore, pleased to find the publication of an updated American Heart Association (AHA) 
scientific statement for the management of pediatric infective endocarditis (IE) written by 
Baltimore et al1 (referred to from here on as the 2015 IE Update), which was based both on 
evidence and expert opinion. However, given our clinical expertise with optimizing antibiotic 
dosing in children, we found a number of the recommendations to be less than ideal. When 
taking into account drug-specific pharmacokinetic (PK) and pharmacodynamics (PD) parameters 
as well as current medical evidence, it becomes clear that application of the guideline-
recommended antibiotic doses could result in a suboptimal antibiotic regimen. Because PK/PD 
parameters were given significant weight in the adult endocarditis guidelines and 
recommendations, we find it perplexing that these variables were not considered in the pediatric 
patient population.2 This is especially important given that antibiotic PK/PD characteristics in 
children can be quite different in comparison to the adult cohort. 
 
For any infection, especially those that are difficult to treat, such as IE, the goal is to optimize 
antibiotic doses to meet PK/PD targets to increase the likelihood of positive patient outcomes 
while minimizing unnecessary toxicity and development of resistance. Established efficacy-
associated PD parameters (Table 1) should be considered when recommending or administering 
an antibiotic regimen.3,4 Although limited, there is an increasing body of evidence suggesting 
positive outcomes associated with optimized dosing strategies that incorporate efficacy 
predictors such as length of time free drug concentrations exceed the minimum inhibitory 
concentration for the bacterial pathogen (fT>MIC), area under the curve for plasma 
concentration relative to organism MIC (AUC:MIC), or maximum serum concentration relative 
to organism MIC (C max :MIC). While the expertise of the authors involved in the 2015 IE 
Update is robust, a consensus on pediatric dosing is incomplete without including the opinion of 
a pediatric pharmacist expert. Pediatric clinical pharmacists with expertise in infectious diseases 
positively affect patient care through their knowledge and experience in optimizing antibiotic 
dosing based on PK/PD parameters, and their opinions should be solicited and included during 
the development of organizational guidelines and recommendations.5-8 We appreciate the 
suggestion to consult pharmacists in certain circumstances found in the footnotes to table 7 in 
their article and in the section regarding antibiotic blood levels. However, in the case of the 2015 
IE Update, a pediatric pharmacist was not included in the panel, which may be a reason for 
omitting PK/PD considerations within their recommendations and dosing algorithms. 
 
 
 
 
Vancomycin 
We agree that the vancomycin dosing recommendation of 60 mg/kg/d divided every 6 hours is 
appropriate for many children, but a combination of factors, including comorbidities, renal 
function, and severity of illness, should be considered when choosing initial vancomycin 
regimens. A 6-hour dosing interval is likely unnecessary and potentially harmful for some 
children, particularly those with hemodynamically significant congenital heart disease and renal 
dysfunction or for children 11 years of age and older. PK modeling suggests that in children with 
congenital heart disease, doses between 30 and 40 mg/kg/d, rather than 60 mg/kg/d 
recommended by the 2015 IE Update, predict trough vancomycin concentrations of 
approximately 12 to 16 mg/L.9 Because of the underlying disease state, greater PK variability is 
also observed in these patients.10 
 
The 2015 IE Update recommends a maximum daily vancomycin dose of 2 g without supporting 
evidence, and we posit that using the recommended maximum may result in suboptimal 
AUC:MIC exposures for many patients. For the treatment of streptococci and staphylococci, 
including MRSA (methicillin-resistant Staphylococcus aureus), the dosing recommendation in 
the 2015 IE Update is 40 mg/ kg/d divided every 8 to 12 hours. There is evidence, particularly 
with MRSA, that 40 mg/kg/d is often inadequate to achieve desired AUC:MIC exposures.11,12 
Our personal experience in dosing and monitoring vancomycin in children would support that 40 
mg/kg/d divided every 8 to 12 hours is insufficient for most patients, with previously mentioned 
exceptions. Furthermore, the discussion of vancomycin therapeutic drug monitoring (TDM) 
highlights only trough concentration monitoring, leaving out the importance of AUC:MIC target 
attainment. Positive outcomes with vancomycin are best predicted by achievement of an 
AUC:MIC of ≥400:1, which may or may not be accurately predicted by trough concentrations in 
children.13 Area under the curve monitoring, using 2 concentrations or Bayesian software, may 
be a more appropriate monitoring parameter for efficacy.13 Although it is recognized that other 
dosing references may be more appropriate for in-depth discussions and drug dosing 
recommendations, the 2015 IE Update as written gives the impression that the contained 
information is sufficient for provision of care of all pediatric patients. Important additions to the 
vancomycin TDM risk-benefit discussion include the lack of studies in children correlating 
attainment of trough concentration targets with efficacy and evidence that higher trough 
concentrations (≥15 mg/L) may be associated with acute kidney injury.13-15 
 
Aminoglycosides 
The 2015 IE Update acknowledges that extended-interval aminoglycosides (EIA) are frequently 
used and are recommended by a similar adult panel but state that a recommendation for EIA in 
children cannot be made because of lack of evidence.1 This optimized dosing strategy can and 
should be used in children as well as in adults (Table 1). Interestingly, the recommended 
aminoglycoside dosing provided in table 7 of the 2015 IE Update is the same for Gram-negative 
enteric bacilli and Gram-positive organisms at 3 to 6 mg/ kg/d despite different peak serum 
concentration goals. It is acknowledged later in the antibiotic blood level monitoring section that 
higher doses (7.5 mg/kg/dose) may be needed to attain the desired peak concentration for Gram-
negative organisms, but this is not reflected in the table. Furthermore, this section on goal 
monitoring provides goal peak and trough recommendations without regard to the MIC of the 
offending organism, despite a goal C max :MIC ratio of 10:1 for Gram-negative pathogens.
4 
Undetectable concentrations at the end of the interval provide reduced likelihood of 
nephrotoxicity regardless of dosing regimen.4 Evidence to support goal gentamicin peak 
concentrations in the treatment of endocarditis is based on in vitro and animal data, and further 
studies are needed. 
 
β-Lactams 
Cefepime is a time-dependent bactericidal antibiotic with optimal efficacy determined by 
fT>MIC, but it has a relatively short half-life and one that is shorter in children than in adults.16 
Because IE can be so difficult to treat, we assert that based on simulated PD target data, 
cefepime should be dosed no less than every 8 hours in individuals with normal renal function, 
particularly when pathogen MICs are 1 or greater.17 This is of particular importance, given that 
adequate treatment of many pathogens with cefepime requires aggressive dosing and the 
implementation of  “susceptible dose-dependent” as an interpretive criteria.18 Specifically, 
Enterobacteriaceae with cefepime MICs of 4 and 8 mg/L are more likely to experience clinical 
failure when treated with cefepime in low doses, so aggressive dosing is warranted.18 
 
Piperacillin/tazobactam is also a time-dependent bactericidal antibiotic with a short half-life.19 
Published PK/PD data do not support the 2015 IE Update recommended dosing of 240 mg/kg 
divided every 8 hours, on the basis that it is suboptimal and unlikely to provide desired target 
attainment, particularly for pathogens with elevated MICs.17,20 The 2015 IE Update seems to 
apply PK/PD concepts with ampicillin/sulbactam dosing recommendations (every 4 hours), but 
the paradigm does not appear to have been considered for piperacillin/tazobactam and cefepime. 
In patients with normal renal function, we do not believe that piperacillin/tazobactam is 
optimally dosed at every 8-hour dosing unless given as an extended infusion. We promote dose 
and infusion optimization based on the organism MIC. Though comparative outcomes data are 
limited, delivery of antibiotics such as penicillin and nafcillin by continuous infusion is an 
administration strategy that may provide consistent concentrations at the site of infection while 
limiting frequent manipulation of the IV catheter, which is known to increase the risk of 
infection, and limiting the number of doses required to be administered by nursing and prepared 
by the pharmacy department.21 
 
Conclusions 
The 2015 IE Update includes antibiotic dosing recommendations that generally should be 
considered in context to each patient; it is not a binding document requiring strict adherence. 
There can be a hesitance to deviate from guideline recommendations in part because it is difficult 
for a provider to critically evaluate and distinguish between the recommendations derived from 
quality studies and those from a consensus of experts. The discussion surrounding dosing 
recommendations in the 2015 IE Update is limited and further impairs the general provider by 
creating uncertainty regarding the availability or absence of supporting rationale for a specific 
recommendation, such as the maximum dose for vancomycin. In the absence of clear rationale, 
the provider is likely to either follow the evidence with which they are acquainted or to follow 
the recommendations of the expert panel, which may be inadequate and/or ultimately harmful to 
many pediatric patient populations. 
 
There is an opportunity to improve the antibiotic dosing recommendations contained within the 
2015 Pediatric Infective Endocarditis Update.1 We have highlighted our areas of disagreement 
with the 2015 IE Update and included optimized dosing strategies for these antibiotics in Table 
1. Efforts can be taken to bridge the gap between the quest for evidence-based recommendations 
in the setting of limited well-designed comparative studies and expert-based opinions that result 
in suboptimal dosing based on existing PK/ PD data. Inclusion of a pediatric pharmacist expert in 
the development of antibiotic dosing recommendations contained within guidelines could be an 
appropriate first step and would broaden the overall perspective of the expert panel. We 
recommend that the AHA involves a pediatric pharmacist with expertise in optimizing antibiotic 
dosing, specifically considering PK/PD differences throughout the pediatric developmental 
continuum, in future updates of this guideline or any guideline in which antibiotic doses are 
recommended. We also recommend that prescribers and pharmacists providing care for children 
with endocarditis consider the origin of guideline-recommended antibiotic doses while balancing 
knowledge of fundamental PK/PD principles and available evidence. 
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